Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Shanghai INT Medical Instruments Co's 3-Year RORE % for the quarter that ended in Dec. 2025 was 8.00%.
HKSE:01501's 3-Year RORE % is ranked better than 61.15% of 785
companies
in the Medical Devices & Instruments industry
Industry Median: -2.45
vs HKSE:01501: 8.00
Shanghai INT Medical Instruments Co (HKSE:01501) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Shanghai INT Medical Instruments Co 3-Year RORE % Related Terms
Shanghai INT Medical Instruments Co 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai INT Medical Instruments Co 3-Year RORE % Chart
HKSE:01501 vs ISRG, BDX, RMD: 3-Year RORE % Comparison
For the Medical Instruments & Supplies subindustry, Shanghai INT Medical Instruments Co's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai INT Medical Instruments Co 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shanghai INT Medical Instruments Co's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Shanghai INT Medical Instruments Co's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Shanghai INT Medical Instruments Co (HKSE:01501) has a 3-Year RORE % of 8.00 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Shanghai INT Medical Instruments Co and its competitors. According to the industry distribution chart, Shanghai INT Medical Instruments Co ranks #305 out of 785 companies in the Medical Devices & Instruments industry, placing it in the top 38.9%.
Is Shanghai INT Medical Instruments Co's 3-Year RORE % too high?
Shanghai INT Medical Instruments Co's current 3-Year RORE % is 8.00. Based on the distribution chart, Shanghai INT Medical Instruments Co ranks #305 out of 785 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shanghai INT Medical Instruments Co has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai INT Medical Instruments Co's 3-Year RORE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Shanghai INT Medical Instruments Co ranks #305 out of 785 companies for 3-Year RORE %. This puts Shanghai INT Medical Instruments Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Shanghai INT Medical Instruments Co and its competitors. Shanghai INT Medical Instruments Co's current 3-Year RORE % is 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai INT Medical Instruments Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai INT Medical Instruments Co (HKSE:01501) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$40.45, compared to a current price of HK$34.10 — trading 15.7% below its estimated fair value. The current 3-Year RORE % is 8.00. Shanghai INT Medical Instruments Co's overall GF Score™ is 94/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Shanghai INT Medical Instruments Co (HKSE:01501), the current 3-Year RORE % is 8.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai INT Medical Instruments Co (HKSE:01501) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai INT Medical Instruments Co stock appears to be undervalued.
The current stock price of HK$34.10 is trading 15.7% below its estimated GF Value™ of HK$40.45.
GuruFocus considers Shanghai INT Medical Instruments Co to be Modestly Undervalued.
Key valuation signals for HKSE:01501:
3-Year RORE %: 8.00
GF Value™: HK$40.45 vs. price of HK$34.10 (15.7% below fair value)
No single metric tells the full story. See the HKSE:01501 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai INT Medical Instruments Co Ltd engages in the design and development of medical devices used in fields including peripheral intervention, neurological intervention, cardiovascular intervention, or implantation, and the design and development of equipment and moulds used for the production of medical devices. The company operates in the Chinese Mainland, Europe, the United States, and Other countries and regions. The majority of the revenue comes from the Chinese Mainland.
94GF Score
Get the complete analysis for HKSE:01501
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01501 has been successfully added to your 
